BRPI0409935A - composição para aperfeiçoar percepção e memória - Google Patents

composição para aperfeiçoar percepção e memória

Info

Publication number
BRPI0409935A
BRPI0409935A BRPI0409935-4A BRPI0409935A BRPI0409935A BR PI0409935 A BRPI0409935 A BR PI0409935A BR PI0409935 A BRPI0409935 A BR PI0409935A BR PI0409935 A BRPI0409935 A BR PI0409935A
Authority
BR
Brazil
Prior art keywords
impairment
memory
melatonin
nicotine
composition
Prior art date
Application number
BRPI0409935-4A
Other languages
English (en)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of BRPI0409935A publication Critical patent/BRPI0409935A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO PARA APERFEIçOAR PERCEPçãO E MEMóRIA". A invenção se refere a uma combinação farmacologicamente ativa, tendo utilidade no tratamento de pacientes com insónia, que compreende (a) pelo menos um ingrediente ativo selecionado a partir da melatonina, outros agentes melatonérgicos, agonísticos de melatonina e antagonistas de melatonina; e (b) pelo menos um segundo ingrediente ativo selecionado a partir da nicotina e agonísticos receptores de nicotina; ao uso de um medicamento contendo componente (a) com ou sem componente (b) para aliviar pelo menos um efeito adverso que ocorre em um paciente no curso de terapia de substituição de nicotina, ou de outro modo, selecionado a partir do prejuízo da qualidade do sono, prejuízo da percepção e prejuízo da memória, bem como a um kit tendo utilidade no tratamento de pacientes com insónia, que compreende os componentes (a) e (b) na forma de unidade de dosagem.
BRPI0409935-4A 2003-04-29 2004-04-15 composição para aperfeiçoar percepção e memória BRPI0409935A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL155666A IL155666A (en) 2003-04-29 2003-04-29 Insomnia treatment
PCT/IL2004/000330 WO2004096118A2 (en) 2003-04-29 2004-04-15 Composition for improving cognition and memory

Publications (1)

Publication Number Publication Date
BRPI0409935A true BRPI0409935A (pt) 2006-04-25

Family

ID=33397641

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409935-4A BRPI0409935A (pt) 2003-04-29 2004-04-15 composição para aperfeiçoar percepção e memória

Country Status (28)

Country Link
US (2) US8859593B2 (pt)
EP (1) EP1620058B1 (pt)
JP (2) JP4981440B2 (pt)
KR (1) KR101136885B1 (pt)
CN (1) CN1787820B (pt)
AR (1) AR048370A1 (pt)
AT (1) ATE539746T1 (pt)
BR (1) BRPI0409935A (pt)
CA (1) CA2521182C (pt)
CL (1) CL2004000877A1 (pt)
CY (1) CY1112689T1 (pt)
DK (1) DK1620058T3 (pt)
EA (1) EA008768B1 (pt)
ES (1) ES2380364T3 (pt)
IL (1) IL155666A (pt)
IS (1) IS8090A (pt)
MX (1) MXPA05011590A (pt)
NO (1) NO333015B1 (pt)
NZ (1) NZ542724A (pt)
PE (1) PE20050144A1 (pt)
PL (1) PL1620058T3 (pt)
PT (1) PT1620058E (pt)
SI (1) SI1620058T1 (pt)
TW (1) TWI340037B (pt)
UA (1) UA87980C2 (pt)
UY (1) UY28296A1 (pt)
WO (1) WO2004096118A2 (pt)
ZA (1) ZA200509508B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP4993900B2 (ja) * 2005-11-28 2012-08-08 国立大学法人 東京医科歯科大学 記憶障害抑制剤
US8372876B2 (en) * 2007-03-06 2013-02-12 The University Of Houston System Method for improving memory in mammals
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
RU2459624C2 (ru) * 2007-04-12 2012-08-27 Риджентс Оф Дзе Юниверсити Оф Миннесота Защитные композиции от ишемии/реперфузии и способы применения
CA3085116C (en) 2012-01-26 2022-07-19 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102148990B1 (ko) * 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
CN107810003B (zh) * 2015-02-04 2022-05-03 索尔约瑟法梅内德斯公司 包含瓦伦托宁的透皮治疗系统及其作为药物的应用
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
KR102499141B1 (ko) * 2016-10-31 2023-02-13 신신제약 주식회사 수면장애 치료용 경피흡수제제
MX386987B (es) 2016-10-31 2025-03-19 Neurim Pharma 1991 Mini-tabletas de melatonina y métodos de fabricación de las mismas.
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468017A (en) * 1892-02-02 Lock-case
US4506080A (en) 1983-07-01 1985-03-19 Nestec S. A. Preparation of serotonine and derivatives
US4965074A (en) 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4765985A (en) 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
ES2028074T3 (es) 1986-06-13 1992-07-01 Alza Corporation Activacion por humedad de un sistema de suministro transdermico de farmacos.
DE3639418A1 (de) 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
PT100973A (pt) 1991-10-18 1994-06-30 Alza Corp Dispositivo e composicoes farmaceuticas para a administracao de melatonina por via transdermica
JPH07506720A (ja) * 1992-01-07 1995-07-27 アテナ　ニューロサイエンシーズ，　インコーポレイテッド アルツハイマー病のトランスジェニック動物モデル
ATE141051T1 (de) 1992-04-07 1996-08-15 Neurim Pharma 1991 Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
AU7323794A (en) 1993-07-09 1995-02-06 Cygnus Therapeutic Systems Method and device for providing nicotine replacement therapy transdermally/transbuccally
CA2187023A1 (en) 1994-04-13 1995-10-26 Steven Andrew Giannos Temporally controlled drug delivery systems
US6017887A (en) 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
WO1996023496A1 (en) 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
US5696115A (en) 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal
US5700828A (en) 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
US6183775B1 (en) 1996-05-13 2001-02-06 Novartis Consumer Health S.A. Buccal delivery system
FR2762993B1 (fr) * 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
NZ500643A (en) * 1997-05-30 2001-12-21 Neurosearch As Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators
AU3364499A (en) * 1998-03-25 1999-10-18 New York University Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
US6353015B1 (en) 1998-08-26 2002-03-05 St. Elizabeth's Medical Center Method of treating neurodegenerative disorders
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
DK1150661T3 (da) 1999-02-05 2004-03-01 Cipla Ltd Topiske sprays der omfatter et filmdannende præparat
US6353051B1 (en) 1999-03-10 2002-03-05 E. I. Du Pont De Nemours And Company Top coating for synthetic leathers
HK1052655A1 (zh) 2000-01-05 2003-09-26 纽里姆药品(1991)有限公司 用於治療對抗高血壓藥的抗藥性和相關病症的方法和製劑
WO2001066114A1 (en) * 2000-03-03 2001-09-13 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
DE10013712A1 (de) 2000-03-20 2001-09-27 Nutrinova Gmbh Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
CN1553771A (zh) 2001-03-26 2004-12-08 史密丝克莱恩比彻姆公司 含烟碱的口服剂量形式
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
DE60105820D1 (de) 2001-10-22 2004-10-28 Pera Ivo E Zusammensetzung zur Reduzierung oder Entwöhnung von Nikotinabhängigkeit
US7113651B2 (en) 2002-11-20 2006-09-26 Dmetrix, Inc. Multi-spectral miniature microscope array
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment

Also Published As

Publication number Publication date
CN1787820A (zh) 2006-06-14
ZA200509508B (en) 2006-11-29
US8859593B2 (en) 2014-10-14
CN1787820B (zh) 2010-05-05
US20140378512A1 (en) 2014-12-25
AR048370A1 (es) 2006-04-26
EP1620058B1 (en) 2012-01-04
HK1087635A1 (zh) 2006-10-20
NO333015B1 (no) 2013-02-18
JP2012116859A (ja) 2012-06-21
WO2004096118A2 (en) 2004-11-11
SI1620058T1 (sl) 2012-05-31
EA200501666A1 (ru) 2006-06-30
IL155666A (en) 2013-12-31
CA2521182A1 (en) 2004-11-11
WO2004096118A3 (en) 2005-10-13
ES2380364T3 (es) 2012-05-11
NO20055531L (no) 2005-11-23
PL1620058T3 (pl) 2012-07-31
IS8090A (is) 2005-10-25
KR20060005402A (ko) 2006-01-17
DK1620058T3 (da) 2012-05-07
WO2004096118B1 (en) 2005-12-01
KR101136885B1 (ko) 2012-04-20
MXPA05011590A (es) 2006-03-08
US20060229340A1 (en) 2006-10-12
PE20050144A1 (es) 2005-05-12
JP4981440B2 (ja) 2012-07-18
UA87980C2 (ru) 2009-09-10
EA008768B1 (ru) 2007-08-31
ATE539746T1 (de) 2012-01-15
PT1620058E (pt) 2012-04-13
CL2004000877A1 (es) 2005-01-07
NZ542724A (en) 2007-05-31
UY28296A1 (es) 2004-11-30
EP1620058A2 (en) 2006-02-01
JP2006525317A (ja) 2006-11-09
TW200501948A (en) 2005-01-16
CA2521182C (en) 2011-05-31
EP1620058A4 (en) 2006-07-26
CY1112689T1 (el) 2016-02-10
IL155666A0 (en) 2004-09-27
TWI340037B (en) 2011-04-11

Similar Documents

Publication Publication Date Title
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
CY1112689T1 (el) Συνθεση για τη βελτιωση της γνωσης και της μνημης
ATE454140T1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
BR0206979A (pt) Métodos e composições para reduzir o paladar de agentes farmaceuticamente ativos
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
PY0218122A (es) Metodo para el tratamiento del insomnio primario
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
WO2008120966A1 (es) Composición farmacéutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgésico opiáceo para el manejo del dolor.
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
PT1408977E (pt) Terapia de combinacao para o tratamento de falha cardiaca
EA200802159A1 (ru) Введение агониста-антагониста пациентам с опиоидной зависимостью
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
MA63498A1 (fr) Formes posologiques orales d'ibrutinib
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
DE60008589D1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
TH69871A (th) องค์ประกอบสำหรับปรับปรุงกระบวนการรับรู้และความจำให้ดีขึ้น
TH70531B (th) องค์ประกอบสำหรับปรับปรุงกระบวนการรับรู้และความจำให้ดีขึ้น
SE9803158D0 (sv) A new composition
KR880013556A (ko) 도파민수용체 효능제의 용도
Stojanovic Comparative Review of Gingival Retraction Agents
BR0316192A (pt) Método e composições para o tratamento da ansiedade

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/405; A61P 5/00

Ipc: A61K 31/405 (2011.01), A61P 5/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 31/405 , A61P 5/00

Ipc: A61K 31/4045 (2006.01), A61K 31/405 (2006.01), A61

Ipc: A61K 31/4045 (2006.01), A61K 31/405 (2006.01), A61

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL